ScholarIQanswers from OpenAlex

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival

PaperCitations, authors & open-access status

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival have?

ScholarIQcitation count

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival has 245 citations in the OpenAlex counts ScholarIQ stores.

When was Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival published?

ScholarIQyear

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival has 2008 year in the ScholarIQ index.

What is the open-access status of Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival?

ScholarIQoa status

Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival has closed oa status in the ScholarIQ index.

What is the DOI of Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival?

ScholarIQdoi

The DOI for Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival is on the source record.

What is the PMID of Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival?

ScholarIQpmid

The PMID for Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival is on the source record.

What is the OpenAlex record for Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival?

ScholarIQopenalex

The OpenAlex for Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial